JCM
IMUC

Jacobi Capital Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Jacobi Capital Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-125
Closed – – 1056
2018
Q3 		$0 Hold
125
– – ﹤0.01% 1091
2018
Q2 		$0 Hold
125
– – ﹤0.01% 1074
2018
Q1 		$0 Hold
125
– – ﹤0.01% 1037
2017
Q4 		$0 Hold
125
– – ﹤0.01% 977
2017
Q3 		$0 Hold
125
– – ﹤0.01% 958
2017
Q2 		$0 Hold
125
– – ﹤0.01% 878
2017
Q1 		$0 Hold
125
– – ﹤0.01% 750
2016
Q4 		$0 Hold
125
– – ﹤0.01% 772
2016
Q3 		$1K Hold
125
– – ﹤0.01% 709
2016
Q2 		$1K Buy
+125
New +$1.29K ﹤0.01% 709

Other funds holding IMUC

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Jacobi Capital Management's IMUC Position: Q4 2018 in Review

Jacobi Capital Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 125 shares.

Jacobi Capital Management first reported a position in IMUC in Q2 2016 and held it in 10 quarters. The position peaked at $1K in Q3 2016. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

  • Jacobi Capital Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
  • Jacobi Capital Management sold 125 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018.
  • Jacobi Capital Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2016 and held it in 10 quarters.
  • Jacobi Capital Management's ImmunoCellular Therapeutics, Ltd. position peaked at $1K in Q3 2016.
  • 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on Jacobi Capital Management's 13F filing for Q4 2018, filed 11 Feb 2019.